Fresenius Medical Care Partners with JMS Co. Ltd. to Advance Home Dialysis Treatment in Japan
17 September 2021 - 5:12PM
Business Wire
Innovative home dialysis therapies to
support Japan’s growing dialysis needs
Fresenius Medical Care, the world’s leading provider of products
and services for individuals with renal diseases, has today
announced a strategic distribution partnership with JMS Co. Ltd, a
provider of medical devices and pharmaceuticals, in Japan. Under
the agreement, JMS Co. Ltd. will distribute Fresenius Medical
Care’s innovative home dialysis therapies in the Japanese market,
providing patients with a wider range of dialysis choices to suit
their lifestyle, enhance their wellbeing, and to help address the
home healthcare needs of Japan’s aging population.
Japan has what is known as a ‘super-aging society’, with the
largest elderly population in the world.1 By 2035, it is projected
that 33 per cent of the total population will be aged 65 and over.1
Alongside this accelerated aging, the number of people requiring
dialysis in Japan continues to grow each year. At the end of 2018,
there were 339,841 people in Japan undergoing dialysis with an
average age of almost 69 years.2 Yet the vast majority of these
people receive their treatment in dialysis centers, with only 3 per
cent undergoing home dialysis – the lowest percentage of home
dialysis users in the developed world.2 The combination of
increased aging population and dialysis need is placing pressure on
the Japanese healthcare system, and it is mandatory for Japanese
society to find a solution to these issues for sustainaiblity.3
Expanding the opportunities for home dialysis has the potential
to provide clinical benefits to patients, as well as offer greater
treatment flexibility that can improve quality of life.4 Home
dialysis allows patients to have treatment in the familiar
surroundings of their own home, where they can take an active
hands-on role in their own care, while avoiding the need to travel
to a clinic - and therefore enjoy more flexibility to work, study
and/or socialize.4
“Fresenius Medical Care is committed to improving patients’
quality of life through our expertise in chronic kidney disease
management”, said Mr Harry de Wit, CEO & President of Fresenius
Medical Care Asia Pacific. “Through providing various treatments
options to healthcare professionals and patients, we aim to deliver
on our vision – to create a future worth living, for patients,
worldwide, every day”.
“We are happy to form this strategic partnership with JMS, as we
share the same vision about the future of home therapy in Japan. We
are confident that our partnership will bring substantial benefits
to the Japanese community,” said Mrs Jean DeSombre, Executive Vice
President for Mature Asia, Fresenius Medical Care Asia Pacific.
Under the agreement, JMS Co. Ltd will distribute the advanced
portfolio of Fresenius Medical Care’s home dialysis systems in
Japan, including automatic peritoneal dialysis system. These
systems, which have US Federal Drug Authority (FDA) and European CE
Mark approvals, are used widely in other developed countries.
ENDS
References
- Iwata, H., Matsushima, M., Watanabe, T., Sugiyama, Y.,
Yokobayashi, K., Son, D., Satoi, Y., Yoshida, E., Satake, S.,
Hinata, Y. and Fujinuma, Y., 2020. The need for home care
physicians in Japan – 2020 to 2060. BMC Health Services Research,
20(1), pp.1-11.
- Nitta, K., Goto, S., Masakane, I., Hanafusa, N., Taniguchi, M.,
Hasegawa, T., Nakai, S., Wada, A., Hamano, T., Hoshino, J., Joki,
N., Abe, M., Yamamoto, K. and Nakamoto, H., 2020. Annual dialysis
data report for 2018, JSDT Renal Data Registry: survey methods,
facility data, incidence, prevalence, and mortality. Renal
Replacement Therapy, 6(1), pp.1-18.
- Hanafusa, N. and Fukagawa, M., 2020. Global Dialysis
Perspective: Japan. Kidney360, 1(5), pp.416-419.
- Walker, R., Howard, K. and Morton, R., 2017. Home hemodialysis:
a comprehensive review of patient-centered and economic
considerations. ClinicoEconomics and Outcomes Research, Volume 9,
pp.149-161.
ABOUT FRESENIUS MEDICAL CARE
Fresenius Medical Care is the world's leading provider of
products and services for individuals with renal diseases of which
around 3.7 million patients worldwide regularly undergo dialysis
treatment. Through its network of more than 4,100 dialysis clinics,
Fresenius Medical Care provides dialysis treatments for
approximately 346,000 patients around the globe. Fresenius Medical
Care is also the leading provider of dialysis products such as
dialysis machines or dialyzers. Along with its core business, the
Renal Care Continuum, the company focuses on expanding in
complementary areas and in the field of critical care. Fresenius
Medical Care is listed on the Frankfurt Stock Exchange (FME) and on
the New York Stock Exchange (FMS).
For more information visit the Company’s website at
www.freseniusmedicalcare.asia.
DISCLAIMER
This release contains forward-looking statements that are
subject to various risks and uncertainties. Actual results could
differ materially from those described in these forward-looking
statements due to various factors, including, but not limited to,
changes in business, economic and competitive conditions, legal
changes, regulatory approvals, impacts related to the COVID-19
pandemic results of clinical studies, foreign exchange rate
fluctuations, uncertainties in litigation or investigative
proceedings, and the availability of financing. These and other
risks and uncertainties are detailed in Fresenius Medical Care AG
& Co. KGaA's reports filed with the U.S. Securities and
Exchange Commission. Fresenius Medical Care AG & Co. KGaA does
not undertake any responsibility to update the forward-looking
statements in this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210917005139/en/
Media Dr. Alexandra Villar Vice President Corporate
Communications and Branding Asia Pacific
Fresenius Medical Care 51/F Sun Hung Kai Centre, 30
Harbour Road Wanchai, Hong Kong Alexandra.Villar@fmc-asia.com
www.freseniusmedicalcare.asia
For further information: Dr Alexandra Villar:
Alexandra.Villar@fmc-asia.com
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2024 to May 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From May 2023 to May 2024